Related Experiment Video
Updated: May 17, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Variations in adiponectin levels in patients with chronic kidney disease: a prospective study of 12 months
Maria Ayako Kamimura1, Maria Eugênia Fernandes Canziani, Fabiana Ribeiro Sanches
1Programa de Pós-Graduação em Nutrição, EPM, Universidade Federal de São Paulo.
Insights
In chronic kidney disease (CKD) patients, adiponectin levels are linked to age, sex, GFR, and visceral fat. Increased visceral fat over time independently predicts lower adiponectin levels.
Area of Science:
- Nephrology
- Endocrinology
- Cardiology
Background:
- Cardiovascular complications are a leading cause of mortality in chronic kidney disease (CKD).
- Adiponectin, an adipose-derived protein, possesses cardioprotective properties.
- Understanding adiponectin determinants in CKD is crucial for managing cardiovascular risk.
Purpose of the Study:
- To investigate the factors influencing adiponectin levels in patients with chronic kidney disease.
- To determine the relationship between adiponectin and clinical, biochemical, and body composition parameters in CKD.
- To assess the longitudinal association between changes in body fat and adiponectin levels over 12 months.
Main Methods:
- A prospective observational study involving 98 non-dialyzed CKD patients.
- Baseline and 12-month assessments included adiponectin levels, glomerular filtration rate (GFR), proteinuria, body mass index (BMI), and abdominal fat (visceral and subcutaneous) via computed tomography.
- Statistical analyses included correlation and linear regression to identify determinants of adiponectin.
Main Results:
- Adiponectin levels correlated negatively with GFR, BMI, and visceral fat, and positively with proteinuria.
- Independent predictors of adiponectin at baseline were female sex, age, GFR, and visceral fat.
- Over 12 months, CKD progression was observed (decreased GFR, increased proteinuria), accompanied by increased visceral fat and a significant reduction in adiponectin levels.
- Increased visceral fat independently predicted the decrease in adiponectin over time.
Conclusions:
- Adiponectin levels in non-dialyzed CKD patients are independently associated with age, sex, renal function (GFR), and visceral fat.
- Changes in visceral fat are the primary predictor of adiponectin level variations over a 12-month period in this population.
- Targeting visceral fat may be a strategy to modulate adiponectin levels and potentially mitigate cardiovascular risk in CKD.
Background:
Cardiovascular complications remain the main cause of mortality in patients with chronic kidney disease (CKD). Adiponectin is an adipose tissue-derived protein that carries important cardioprotective properties. We aimed at investigating the determinants of adiponectin levels in CKD patients.
Methods:
This prospective observational study included 98 CKD patients [glomerular filtration rate (GFR) 36.1+-14.4 ml/min, 56.5+-10.4 y, 63% male, 31% diabetics, and body mass index (BMI) 27.1+-5.2 kg/m²]. Evaluation of adiponectin (imunoenzimatic assay), laboratory parameters, nutritional status (subjective global assessment), total body fat (dual x-ray energy absorptiometry), and visceral and subcutaneous abdominal fat (computed tomography) was performed at baseline and after 12 months.
Results:
Adiponectin correlated with GFR (r = -0.45; p < 0.001), proteinuria (r = 0.21; p = 0.04), BMI (r = -0.33; p < 0.01), and visceral fat (r = -0.49; p < 0.001). In the linear regression analysis, the determinants of adiponectin levels were sex (female β = 3.8; p < 0.01), age (β = 0.14; p = 0.03), GFR (β = -0.15; p < 0.01) and visceral fat (β = -0.04; p < 0.001) (R² = 0.41). After 12 months, a progression of the disease was evidenced by the reduction of GFR (-1.6+-6.3 ml/min; p = 0.01) and increase of proteinuria (0.3+-0.8 g/d; p < 0.01). An accumulation of visceral fat was observed, from 97+-73 cm² to 111+-82 cm² (p < 0.001), with a concomitant reduction of adiponectin concentration, from 27.6+-7.5 mg/l to 22.2+-11.6 mg/l (p < 0.001). Body weight, BMI, total body fat, and subcutaneous abdominal fat remained unchanged. After adjustments for the baseline determinants of adiponectin, the increase in visceral fat was independently associated with overtime decrease in adiponectin levels (β = -0.04; p = 0.025; R² = 0.21).
Conclusion:
Age, sex, renal function and visceral fat were independently associated with adiponectin levels in nondialyzed CKD patients. However, variation in visceral fat was the only predictor of variation in adiponectin levels over 12 months.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury III: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Diabetic Nephropathy
